| A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. (NCT07016997) | Chiome Bioscience Inc. | 2022-06-27 |
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor (NCT05359445) | Immatics Biotechnologies GmbH | 2022-05-19 |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma (NCT04510636) | University Health Network, Toronto | 2021-12-20 |
| A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors (NCT04861987) | Processa Pharmaceuticals | 2021-06-18 |
| A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors (NCT04859777) | Monopteros Therapeutics Inc. | 2021-04-13 |
| Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents (NCT04310345) | Vanderbilt-Ingram Cancer Center | 2021-03-31 |
| Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (NCT04337580) | Wake Forest University Health Sciences | 2021-03-05 |
| Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies (NCT04640246) | Taiga Biotechnologies, Inc. | 2021-01-25 |
| Arsenic Trioxide for Structural p53 Mutations (NCT04695223) | Shanghai Changzheng Hospital | 2021-01-01 |
| Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers (NCT04092179) | University Health Network, Toronto | 2020-11-05 |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL (NCT04421560) | Dana-Farber Cancer Institute | 2020-08-01 |
| 9-ING-41 in Pediatric Patients With Refractory Malignancies. (NCT04239092) | Actuate Therapeutics Inc. | 2020-06-05 |
| Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy (NCT03941262) | NKGen Biotech, Inc. | 2019-07-15 |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (NCT03686124) | Immatics US, Inc. | 2019-05-14 |
| TCR-engineered T Cells in Solid Tumors: IMA202-101 (NCT03441100) | Immatics US, Inc. | 2019-05-02 |
| Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling (NCT03760952) | Immatics US, Inc. | 2019-02-26 |
| Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents (NCT03765099) | Vanderbilt-Ingram Cancer Center | 2019-02-21 |
| 9-ING-41 in Patients With Advanced Cancers (NCT03678883) | Actuate Therapeutics Inc. | 2019-01-04 |
| Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS (NCT03187288) | University Health Network, Toronto | 2018-05-25 |
| PRecISion Medicine for Children With Cancer (NCT03336931) | Sydney Children's Hospitals Network | 2017-09-05 |
| A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer (NCT03199677) | Chinese Academy of Medical Sciences | 2017-07-01 |
| Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL (NCT02747732) | Meirav Kedmi MD | 2016-12-01 |
| Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer (NCT02630199) | Samsung Medical Center | 2015-12-01 |
| Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors (NCT02222363) | Vivolux AB | 2015-02-18 |
| BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer (NCT01320280) | Universitätsklinikum Hamburg-Eppendorf | 2011-05-01 |
| Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment (NCT01932047) | Samsung Medical Center | 2010-04-01 |
| A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients (NCT00551850) | AVEO Pharmaceuticals, Inc. | 2007-10-01 |
| Molecular Profiling Protocol (SCRI-CA-001) (NCT00530192) | Scottsdale Healthcare | 2006-09-01 |
| Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors (NCT00011414) | National Cancer Institute (NCI) | 2001-02-15 |